CALC (CalciMedica) ROE % Adjusted to Book Value: Negative Equity% (As of Mar. 2026)


CALC CalciMedica Inc CALC
23 GF Score
Price $0.79
! 2 Warning Signs
View Full Analysis

What is CalciMedica ROE % Adjusted to Book Value?

CalciMedica CALC +29.67% 23 ROE % Adjusted to Book Value is Negative Equity% as of Mar. 2026. GuruFocus rates CALC with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

CalciMedica's ROE % for the quarter that ended in Mar. 2026 was Negative Equity. CalciMedica's PB Ratio for the quarter that ended in Mar. 2026 was N/A. CalciMedica's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was Negative Equity.

CalciMedica ROE % Adjusted to Book Value Related Terms

CalciMedica ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for CalciMedica's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CalciMedica ROE % Adjusted to Book Value Chart

CalciMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -74.72 0.00 0.00 -36.68 0.00

CalciMedica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -65.08 -76.62 0.00 0.00 Negative Equity

CALC vs TOVX, PHIO, PHGE: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, CalciMedica's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CalciMedica ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CalciMedica's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CalciMedica's ROE % Adjusted to Book Value falls into.


CALC
23GF Score
CalciMedica Inc CALC
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CalciMedica ROE % Adjusted to Book Value Calculation

CalciMedica's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-761.02% / N/A
=N/A

CalciMedica's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of Negative Equity% mean?
CalciMedica (CALC) has a ROE % Adjusted to Book Value of Negative Equity% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on CalciMedica and its competitors.
Is CalciMedica's ROE % Adjusted to Book Value too high?
CalciMedica's current ROE % Adjusted to Book Value is Negative Equity%. Overall, CalciMedica has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does CalciMedica's ROE % Adjusted to Book Value compare to TOVX and PHIO?
CalciMedica's ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on CalciMedica and its competitors. CalciMedica's current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CalciMedica stock overvalued right now?
CalciMedica (CALC) has a current ROE % Adjusted to Book Value of Negative Equity%. The current ROE % Adjusted to Book Value is Negative Equity%. CalciMedica's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For CalciMedica (CALC), the current ROE % Adjusted to Book Value is Negative Equity% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CalciMedica Business Description

Address 505 Coast Boulevard South, Suite 307, La Jolla, CA, USA, 92037
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
23GF Score

Get the complete analysis for CALC

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.79
Price